Private equity player OrbiMed Advisors, which invests in the life science space, registered to raise a $300 million fund to invest in healthcare companies in Asia, according to an SEC filing.
OrbiMed’s Shanghai- and Mumbai-based Asia PE fund focuses on "opportunities in China and India across all sectors of healthcare, including healthcare services," according to its website.